EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years

Nicolas A Margot iD, Vamshi Jogiraju, Nina Pennetzdorfer, Vidula Naik, Laurie A VanderVeen, John Ling, Renu Singh, Hadas Dvory-Sobol, Onyema Ogbuagu, Sorana Segal-Maurer, Jean-Michel Molina, Martin S Rhee und 1 weitere

The Journal of Infectious Diseases · 02.06.2025 · 231 (5) · 1239-1245

DOI: 10.1093/infdis/jiaf050 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 28.01.2025. Verfasst von Nicolas A Margot und 12 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc, Foster City, California. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Gilead Sciences, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid that was approved for the treatment of heavily treatment-experienced people with HIV-1 harboring multidrug-resistant virus, and it is used in combination with an optimized background regimen (OBR). Resistance analyses conducted after 2 years of lenacapavir treatment in the phase 2/3 CAPELLA study are described.

Methods

CAPELLA enrollment consisted of viremic cases of heavily treatment-experienced people with HIV-1 and resistance to ≥2 drugs per class in at least 3 of the 4 main drug classes. Postbaseline resistance in participants experiencing virologic failure was evaluated by resistance assays (HIV-1 capsid, protease, reverse transcriptase, and integrase genotypic/phenotypic tests). Adherence to OBR was assessed by plasma drug measurement via liquid chromatography–tandem mass spectrometry.

Results

After 2 years, lenacapavir + OBR treatment led to HIV-1 RNA suppression in 82% of participants (missing = excluded). Treatment-emergent capsid resistance occurred in 19% (14/72) of participants, including capsid mutations M66I, Q67H/K/N, K70H/N/R/S, and/or N74D/H/K, which were all associated with functional lenacapavir monotherapy. Seven participants with lenacapavir resistance reattained HIV-1 RNA <50 copies/mL upon OBR resumption or change while maintaining lenacapavir treatment.

Conclusions

Emergence of lenacapavir resistance after 2 years in CAPELLA was a consequence of functional lenacapavir monotherapy. In half of participants with lenacapavir resistance, continued treatment with lenacapavir + active OBR led to HIV-1 RNA resuppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Drug Resistance, ViralAnti-HIV AgentsHumansMaleFemaleAdultMiddle AgedRNA, ViralMutationViral LoadAcetamidesIndazoles

Stichwörter der Autor:innen

HIVcapsidlenacapavirmonotherapymultidrug resistance

Substanzen

Anti-HIV AgentsRNA, VirallenacapavirAcetamidesIndazoles

Autor:innen und Institutionen

  • Gilead Sciences, Inc, Foster City, California.
  • Yale University School of Medicine, New Haven, Connecticut.
  • New York-Presbyterian Queens, Flushing.
  • Hôpital Saint Louis, Paris, France.

ORCID-Profile: Nicolas A Margot

Förderung

  • Gilead Sciences, Inc

Zitieren

APA

Margot, N. A., Jogiraju, V., Pennetzdorfer, N., Naik, V., VanderVeen, L. A., Ling, J., Singh, R., Dvory-Sobol, H., Ogbuagu, O., Segal-Maurer, S., Molina, J. M., Rhee, M. S., & Callebaut, C. (2025). Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years. The Journal of Infectious Diseases, 231(5), 1239-1245. https://doi.org/10.1093/infdis/jiaf050

Vancouver

Margot NA, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen LA, Ling J, et al. Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years. The Journal of Infectious Diseases. 2025;231(5):1239-1245. doi:10.1093/infdis/jiaf050

BibTeX
@article{Margot2025,
  author = {Margot, Nicolas A and Jogiraju, Vamshi and Pennetzdorfer, Nina and Naik, Vidula and VanderVeen, Laurie A and Ling, John and Singh, Renu and Dvory-Sobol, Hadas and Ogbuagu, Onyema and Segal-Maurer, Sorana and Molina, Jean-Michel and Rhee, Martin S and Callebaut, Christian},
  title = {Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {231},
  number = {5},
  pages = {1239--1245},
  doi = {10.1093/infdis/jiaf050}
}
Kostenlos starten →